Skip to main content
Premium Trial:

Request an Annual Quote

Diversa Awarded $1.38M for Proteomics-based Biodefense Research

NEW YORK, June 16 - Diversa will receive $1.38 million from the Department of Defense's chemical and biological defense initiatives fund for proteomics-related biodefense research, the San Diego-based microbial genomics firm said today.

 

The award will support the development of diagnostic and therapeutic antibodies against anthrax as well as the identification of new targets associated with anthrax and plague pathology, the company said.

 

The DOD funds will be applied to three projects at Diversa: the identification of an optimized antibody against anthrax; proteomics analysis of blood serum from the survivors of the fall 2001 anthrax attacks to identify novel targets for therapeutics; and the proteomics-based Identification of novel protein targets associated with plague.

 

The company said its proteomics analysis method relies on 3D liquid chromatography directly coupled with tandem mass spectroscopy.

 

The research is part of Diversa's "Rapid, Antibody-Based Biological Countermeasures" (RABBC) biodefense program, which aims to develop a collection of novel human antibodies for diagnostic detection and immunity protection against pathogens and toxins. 

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.